Company Aldeyra Therapeutics, Inc.

Equities

ALDX

US01438T1060

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.93 ^USD	-0.25%		+1.81%	+11.97%

Apr. 25	Transcript : Aldeyra Therapeutics, Inc. - Special Call
Apr. 04	North American Morning Briefing : Focus Turns to -2-	DJ

Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.

Number of employees: 10

Managers	Title	Age	Since
Todd Brady CEO	Chief Executive Officer	52	05-08-31
Bruce Greenberg DFI	Director of Finance/CFO	56	19-11-30
Caitlin Pazzano PRN	Corporate Officer/Principal	-	21-12-31
Kelly Mizer PRN	Corporate Officer/Principal	-	21-09-30
Stephen Machatha PRN	Corporate Officer/Principal	47	20-12-31
James A. Gow PRN	Corporate Officer/Principal	-	20-03-11

Members of the board	Title	Age	Since
Gary Phillips BRD	Director/Board Member	58	09-04-30
Martin Joyce BRD	Director/Board Member	70	13-09-30
Ben Bronstein BRD	Director/Board Member	74	10-05-31
Todd Brady CEO	Chief Executive Officer	52	05-08-31
Neal Walker BRD	Director/Board Member	54	13-05-31
Richard Douglas CHM	Chairman	71	16-09-12
Nancy Miller-Rich BRD	Director/Board Member	65	20-01-12

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	59,414,489	48,953,902 ( 82.39 %)	0	82.39 %

Name	Equities	%	Valuation
Perceptive Advisors LLC 15.75 %	9,275,851	15.75 %	30 M $
Perceptive Advisors LLC 14.59 %	8,593,586	14.59 %	28 M $
Knoll Capital Management LP 9.297 %	5,475,516	9.297 %	18 M $
Vanguard Fiduciary Trust Co. 6.669 %	3,927,597	6.669 %	13 M $
BlackRock Advisors LLC 5.617 %	3,308,000	5.617 %	11 M $
Todd Brady 2.498 %	1,471,298	2.498 %	5 M $
Verition Fund Management LLC 2.249 %	1,324,834	2.249 %	4 M $
Kennedy Capital Management LLC 2.167 %	1,276,146	2.167 %	4 M $
Dimensional Fund Advisors LP 1.764 %	1,038,652	1.764 %	3 M $
Geode Capital Management LLC 1.736 %	1,022,572	1.736 %	3 M $

Aldeyra Therapeutics, Inc.

131 Hartwell Avenue Suite 320

02421, Lexington

+781 761 4904

http://www.aldeyra.com

address Aldeyra Therapeutics, Inc.(ALDX)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.93 USD

Average target price

9.571 USD

Spread / Average Target

+143.55%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ALDEYRA THERAPEUTICS, INC.	+11.97%	233M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs